Publication not explained

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.

Featured Image

Read the Original

This page is a summary of: Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial, JAMA Ophthalmology, June 2023, American Medical Association (AMA),
DOI: 10.1001/jamaophthalmol.2023.1463.
You can read the full text:

Read

Contributors

The following have contributed to this page